Acuta Capital Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-131,454
| Closed | -$5.17M | – | 54 |
|
|
2023
Q2 | $5.17M | Sell |
131,454
-149,046
| -53% | -$5.26M | 3.5% | 10 |
|
|
2023
Q1 | $6.82M | Sell |
280,500
-80,000
| -22% | -$1.75M | 5.03% | 8 |
|
|
2022
Q4 | $7.72M | Sell |
360,500
-203,107
| -36% | -$4.33M | 4.75% | 8 |
|
|
2022
Q3 | $10.1M | Hold |
563,607
| – | – | 4.35% | 5 |
|
|
2022
Q2 | $5.42M | Buy |
563,607
+24,107
| +4% | +$303K | 3.02% | 12 |
|
|
2022
Q1 | $9.08M | Buy |
539,500
+69,500
| +15% | +$1.03M | 4.24% | 6 |
|
|
2021
Q4 | $7.86M | Sell |
470,000
-665,000
| -59% | -$10.9M | 3.3% | 8 |
|
|
2021
Q3 | $18.4M | Sell |
1,135,000
-115,000
| -9% | -$1.25M | 6.5% | 3 |
|
|
2021
Q2 | $7.89M | Sell |
1,250,000
-329,093
| -21% | -$2.12M | 3.15% | 8 |
|
|
2021
Q1 | $9.76M | Buy |
1,579,093
+366,593
| +30% | +$2.23M | 3.52% | 5 |
|
|
2020
Q4 | $8.38M | Buy |
1,212,500
+410,000
| +51% | +$2.62M | 2.28% | 18 |
|
|
2020
Q3 | $4.53M | Buy |
802,500
+115,000
| +17% | +$548K | 1.23% | 26 |
|
|
2020
Q2 | $3.51M | Buy |
687,500
+548,500
| +395% | +$2.29M | 1.01% | 34 |
|
|
2020
Q1 | $478K | Sell |
139,000
-771,000
| -85% | -$4.51M | 0.23% | 31 |
|
|
2019
Q4 | $7.81M | Buy |
+910,000
| New | +$3.25M | 1.93% | 17 |
|
Acuta Capital Partners's ISEE Position: Q3 2023 in Review
Acuta Capital Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 131,454 shares — an estimated $5.17M sold.
Acuta Capital Partners first reported a position in ISEE in Q4 2019 and held it in 15 quarters. The position peaked at $18.4M in Q3 2021. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Acuta Capital Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Acuta Capital Partners sold 131,454 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $5.17M.
- Acuta Capital Partners first reported a position in IVERIC bio, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
- Acuta Capital Partners's IVERIC bio, Inc. Common Stock position peaked at $18.4M in Q3 2021.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Acuta Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.